Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A compartmentalized microfluidic chip with crisscross microgrooves and electrophysiological electrodes for modeling the blood–retinal barrier

  • Yeste Lozano, José
  • García Ramírez, Marta
  • Illa, Xavi
  • Guimerà-Brunet, Anton
  • Hernández, Cristina
  • Simó, Rafael
  • Villa, Rosa
The interconnection of different tissue-tissue interfaces may extend organ-on-chips to a new generation of sophisticated models capable of recapitulating more complex organ-level functions. Single interfaces are largely recreated in organ-on-chips by culturing the cells on opposite sides of a porous membrane that splits a chamber in two or by connecting the cells of two adjacent compartments through microchannels. However, it is difficult to interconnect more than one interface using these approaches. To address this challenge, we present a novel microfluidic device where cells are arranged in parallel compartments and are highly interconnected through a grid of microgrooves, which facilitates paracrine signaling and heterotypic cell-cell contact between multiple tissues. In addition, the device includes electrodes on the substrate for the measurement of transepithelial electrical resistance (TEER). Unlike conventional methods for measuring the TEER where electrodes are on each side of the cell barrier, a method with only electrodes on the substrate has been validated. As a proof-of-concept, we have used the device to mimic the structure of the blood-retinal barrier by co-culturing primary human retinal endothelial cells (HREC), a human neuroblastoma cell line (SH-SY5Y), and a human retinal pigment epithelial cell line (ARPE-19). Cell barrier formations were assessed by a permeability assay, TEER measurements, and ZO-1 expression. These results validate the proposed microfluidic device with microgrooves as a promising in vitro tool for the compartmentalization and monitoring of barrier tissues., This work is part of the requirements to achieve the PhD degree in Electrical and Telecommunication Engineering at the Universitat Autònoma de Barcelona, and it was supported by grants from Ministerio de Economía y Competitividad (MINECO) (SAF2014-62114-EXP and SAF2016-77784-R) and Fundació La Marató de TV3 (Exp. 201629-10). This work has made use of the Spanish ICTS Network MICRONANOFABS partially supported by MINECO and the ICTS 'NANBIOSIS', more specifically by the Micro-Nano Technology Unit of the CIBER in Bioengineering, Biomaterials & Nanomedicne (CIBER-BBN) at the IMB-CNM., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

  • Bogdanov Baruj, Patricia
  • Ramos Abellan, Hugo
  • Huerta Alonso, Jordi
  • Simó Servat, Olga
  • Hernández Pascual, Cristina
  • Simó Canonge, Rafael
Diabetic retinopathy; Retina; Semaglutide, Retinopatia diabètica; Retina; Semaglutida, Retinopatía diabética; Retina; Semaglutida, Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial. Although this effect was attributed to a rapid decrease in blood glucose levels, a direct deleterious effect of semaglutide on the retina could not be ruled out. In order to shed light on this issue, we have performed a study aimed at testing the direct effect of semaglutide administered by eye drops on retinal neuroinflammation and microvascular abnormalities using the db/db mouse model. Methods: Eye drops containing semaglutide (0.33 mg/mL; 5 μL once/daily) or vehicle (PBS; 5 μL once daily) were administered for 15 days. Results: We found that semaglutide significantly reduced glial activation, as well as the retinal expression of Nuclear factor kB (NF-κB), proinflammatory cytokines (IL-1β, IL-6, IL-18) and Intercellular Adhesion Molecule (ICAM)-1. In addition, semaglutide prevented the apoptosis of cells from the retinal ganglion layer and activated the protein kinase B (AKT) pathway. Finally, a dramatic decrease in vascular leakage was observed in db/db mice treated with semaglutide. All these findings were observed without any change in blood glucose levels and, therefore, can be directly attributed to semaglutide. Conclusions: These experimental findings point to a beneficial rather than a deleterious effect of semaglutide on the retina of subjects with diabetes., This research was funded by grants from the Ministerio de Economía y Competitividad (PI16/00541, PI19/01215 and SAF2016-77784) and the Fundació La Marató TV3 (201629-10). The study funder was not involved in the design of the study.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neurodegeneration in diabetic retinopathy, does it really matter?

  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Stitt, Alan W.|||0000-0002-8647-9918
  • Gardner, Thomas W.
The concept of diabetic retinopathy as a microvascular disease has evolved, in that it is now considered a more complex diabetic complication in which neurodegeneration plays a significant role. In this article we provide a critical overview of the role of microvascular abnormalities and neurodegeneration in the pathogenesis of diabetic retinopathy. A special emphasis is placed on the pathophysiology of the neurovascular unit (NVU), including the contributions of microvascular and neural elements. The potential mechanisms linking retinal neurodegeneration and early microvascular impairment, and the effects of neuroprotective drugs are summarised. Additionally, we discuss how the assessment of retinal neurodegeneration could be an important index of cognitive status, thus helping to identify individuals at risk of dementia, which will impact on current procedures for diabetes management. We conclude that glial, neural and microvascular dysfunction are interdependent and essential for the development of diabetic retinopathy. Despite this intricate relationship, retinal neurodegeneration is a critical endpoint and neuroprotection, itself, can be considered a therapeutic target, independently of its potential impact on microvascular disease. In addition, interventional studies targeting pathogenic pathways that impact the NVU are needed. Findings from these studies will be crucial, not only for increasing our understanding of diabetic retinopathy, but also to help to implement a timely and efficient personalised medicine approach for treating this diabetic complication.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities, Involvement of Oxidative Stress

  • Ramos, Hugo|||0000-0001-6443-7576
  • Bogdanov, Patricia|||0000-0003-0669-4958
  • Sampedro, Joel|||0000-0002-8463-7740
  • Huerta, Jordi|||0000-0002-9908-8051
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
Background: Hyperglycemia-induced oxidative stress plays a key role in diabetic complications, including diabetic retinopathy. The main goal of this study was to assess whether the topical administration (eye drops) of glucagon-like peptide-1 (GLP-1) has any effect on oxidative stress in the retina. Methods: db/db mice were treated with eye drops of GLP-1 or vehicle for three weeks, with db/+ mice being used as control. Studies included the assessment by western blot of the antioxidant defense markers CuZnSOD, MnSOD, glutathione peroxidase and reductase; immunofluorescence measurements of DNA/RNA damage, nitro tyrosine and Ki67 and Babam2 proteins. Results: GLP-1 eye drops protected from oxidative stress by increasing the protein levels of glutathione reductase, glutathione peroxidase and CuZnSOD and MnSOD in diabetic retinas. This was associated with a significant reduction of DNA/RNA damage and the activation of proteins involved in DNA repair in the retina (Babam2) and Ki67 (a biomarker of cell proliferation). Conclusions: GLP-1 modulates the antioxidant defense system in the diabetic retina and has a neuroprotective action favoring DNA repair and neuron cells proliferation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effects of the topical administration of semaglutide on retinal neuroinflammation and vascular leakage in experimental diabetes

  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Bogdanov, Patricia|||0000-0003-0669-4958
  • Ramos, Hugo|||0000-0001-6443-7576
  • Huerta, Jordi|||0000-0002-9908-8051
  • Simó-Servat, Olga|||0000-0003-3483-652X
  • Hernández, Cristina|||0000-0002-3109-1721
Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial. Although this effect was attributed to a rapid decrease in blood glucose levels, a direct deleterious effect of semaglutide on the retina could not be ruled out. In order to shed light on this issue, we have performed a study aimed at testing the direct effect of semaglutide administered by eye drops on retinal neuroinflammation and microvascular abnormalities using the db/db mouse model. Methods: Eye drops containing semaglutide (0.33 mg/mL; 5 µL once/daily) or vehicle (PBS; 5 µL once daily) were administered for 15 days. Results: We found that semaglutide significantly reduced glial activation, as well as the retinal expression of Nuclear factor kB (NF-κB), proinflammatory cytokines (IL-1β, IL-6, IL-18) and Intercellular Adhesion Molecule (ICAM)-1. In addition, semaglutide prevented the apoptosis of cells from the retinal ganglion layer and activated the protein kinase B (AKT) pathway. Finally, a dramatic decrease in vascular leakage was observed in db/db mice treated with semaglu-tide. All these findings were observed without any change in blood glucose levels and, therefore, can be directly attributed to semaglutide. Conclusions: These experimental findings point to a beneficial rather than a deleterious effect of semaglutide on the retina of subjects with diabetes. 0926.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

  • Bogdanov Baruj, Patricia
  • Ramos Abellán, Hugo
  • Huerta Alonso, Jordi
  • Simó Servat, Olga
  • Hernández Pascual, Cristina
  • Simó Canonge, Rafael
Diabetic retinopathy; Retina; Semaglutide, Retinopatia diabètica; Retina; Semaglutida, Retinopatía diabética; Retina; Semaglutida, Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial. Although this effect was attributed to a rapid decrease in blood glucose levels, a direct deleterious effect of semaglutide on the retina could not be ruled out. In order to shed light on this issue, we have performed a study aimed at testing the direct effect of semaglutide administered by eye drops on retinal neuroinflammation and microvascular abnormalities using the db/db mouse model. Methods: Eye drops containing semaglutide (0.33 mg/mL; 5 μL once/daily) or vehicle (PBS; 5 μL once daily) were administered for 15 days. Results: We found that semaglutide significantly reduced glial activation, as well as the retinal expression of Nuclear factor kB (NF-κB), proinflammatory cytokines (IL-1β, IL-6, IL-18) and Intercellular Adhesion Molecule (ICAM)-1. In addition, semaglutide prevented the apoptosis of cells from the retinal ganglion layer and activated the protein kinase B (AKT) pathway. Finally, a dramatic decrease in vascular leakage was observed in db/db mice treated with semaglutide. All these findings were observed without any change in blood glucose levels and, therefore, can be directly attributed to semaglutide. Conclusions: These experimental findings point to a beneficial rather than a deleterious effect of semaglutide on the retina of subjects with diabetes., This research was funded by grants from the Ministerio de Economía y Competitividad (PI16/00541, PI19/01215 and SAF2016-77784) and the Fundació La Marató TV3 (201629-10). The study funder was not involved in the design of the study.